1 ic efficacy, which is based on a mechanistic
rationale.
2 ounter sustained catabolism have therapeutic
rationale.
3 rt experimental observations and mechanistic
rationale.
4 als and only excluded if there is compelling
rationale.
5 enerally poor evidence on which to base this
rationale.
6 RATIONALE:
A potential adverse effect of high folate int
7 RATIONALE:
Aberrant expression of microRNAs (miRNAs) can
8 RATIONALE:
Accurate reference values for spirometry are
9 RATIONALE:
Acute kidney injury (AKI) is common during hi
10 RATIONALE:
Acute kidney injury is a common and severe co
11 RATIONALE:
Acute respiratory distress syndrome (ARDS) is
12 RATIONALE:
Acute respiratory distress syndrome (ARDS) re
13 RATIONALE:
Acute respiratory distress syndrome is charac
14 RATIONALE:
Administration of tuberculosis (TB) vaccines
15 RATIONALE:
Allergen exposure in sensitized individuals w
16 RATIONALE:
Although the second messenger cyclic AMP (cAM
17 RATIONALE:
Ambient air pollution, including black carbon
18 RATIONALE:
AMPK (AMP-activated protein kinase) is a hete
19 RATIONALE:
An increased ventilatory response to exertion
20 This review assesses the mechanistic
rationale and experimental evidence for nutritional inte
21 Next, we discuss the
rationale and potential benefits of risk factor modifica
22 his timely juncture, we provide a scientific
rationale and three policy options for all levels of gov
23 addendum guidelines provide the background,
rationale,
and strength of evidence for each recommendat
24 We provide a mathematical
rationale,
and then demonstrate it experimentally in ind
25 RATIONALE:
Angiogenesis improves perfusion to the ischem
26 RATIONALE:
Aortic valve disease is a cell-mediated proce
27 RATIONALE:
Areas of increased lung attenuation visualize
28 RATIONALE:
Atherosclerotic-arterial occlusions decrease
29 RATIONALE:
Autologous stem cell therapy using human c-Ki
30 ications of HIV-1 diversity, and outline the
rationale behind several polyvalent vaccine design strat
31 This Spotlight article looks at the original
rationale behind the 14-day rule and its relevance today
32 chinensis alpha-amylase, which could be the
rationale behind the disparity in their IC50.
33 e mode, i.e., gamma- and beta-secretase; the
rationale behind these two targets; and the current stat
34 The
rationale behind this treatment is that VNS paired with
35 RATIONALE:
Bronchiolitis is the most common lower respir
36 RATIONALE:
Caffeine in the newborn period shortens the d
37 RATIONALE:
Calmodulinopathies comprise a new category of
38 RATIONALE:
Cardiac fibroblasts (CFs) drive extracellular
39 RATIONALE:
Cardiac progenitor cells are an attractive ce
40 RATIONALE:
Cell-based therapies are a promising option i
41 RATIONALE:
Chronic inflammation is central in the develo
42 RATIONALE:
Chronic obstructive pulmonary disease (COPD)
43 RATIONALE:
Combination lumacaftor/ivacaftor has been sho
44 RATIONALE:
Conventional 3-dimensional (3D) printing tech
45 The inverse
rationale could also be applied to luminance discriminat
46 RATIONALE:
Cryptogenic strokes, those of unknown cause,
47 In this review, we summarize the
rationale,
current evidence, and future directions in AR
48 RATIONALE:
Current diagnosis of chronic hypersensitivity
49 RATIONALE:
Currently, there are no blood-based biomarker
50 RATIONALE:
Cystic fibrosis (CF) lung disease is caused b
51 RATIONALE:
Delivery of Cx43 (connexin 43) to the interca
52 RATIONALE:
Despite direct immediate intervention and the
53 RATIONALE:
Despite the high burden of respiratory diseas
54 RATIONALE:
Differences in the lung microbial community i
55 RATIONALE:
Difficulty of asthma ascertainment and its as
56 RATIONALE:
Diverse B cell responses and functions may be
57 RATIONALE:
Duchenne muscular dystrophy is a severe inher
58 RATIONALE:
During each beat, cardiac myocytes (CMs) gene
59 RATIONALE:
Dysregulated neutrophil functions with age an
60 RATIONALE:
Early onset and progression of lung disease i
61 RATIONALE:
Encephalitis caused by anti-N-methyl-d-aspart
62 RATIONALE:
Endoplasmic reticulum (ER) stress causes the
63 RATIONALE:
Endothelial dysfunction, a major predictor of
64 RATIONALE:
Estimating the probability of finding N2 or N
65 RATIONALE:
Evidence supporting the association of COPD o
66 RATIONALE:
Existing trials of adjunctive vitamin D in th
67 RATIONALE:
Extracorporeal membrane oxygenation (ECMO) is
68 RATIONALE:
Fatty acids (FA) are transported across the c
69 RATIONALE:
Following acute respiratory distress syndrome
70 This highly powered study provides strong
rationale for a confirmatory phase III clinical trial.
71 This rapidly changing scenario provides a
rationale for a more systematic collection of patient-re
72 ve metastasis, and provide a mechanism-based
rationale for a stroma-directed therapy for PDAC.
73 blocks metastatic spread, thus providing the
rationale for a therapeutic strategy based on PIN1 inhib
74 The first structural
rationale for acetone carboxylation is presented here, f
75 We outline biophysical and evolutionary
rationale for broad variation in protein family sizes, p
76 he core pharmacophore for MC4R and provide a
rationale for careful assay selection for agonist screen
77 The results provide a
rationale for categorizing fluid-feeding insects into tw
78 EAC in a preclinical model, establishing the
rationale for clinical testing.
79 These features provide a strong
rationale for combination immunotherapy approaches with
80 Furthermore, our results provide a strong
rationale for combination treatment strategies targeting
81 tance mechanism to gemcitabine and provide a
rationale for combining chemo/radiotherapy with TIMP1 in
82 Our work provides a
rationale for continued development of a structural fram
83 The data provide
rationale for developing TCRm antibodies as therapeutic
84 Moreover, our work also provides a
rationale for development of CXCR2 antagonists to inhibi
85 The details regarding the evidence and
rationale for each recommendation are presented in the A
86 Rationale for excluding patients should be clearly artic
87 outcomes should be included absent specific
rationale for exclusion.
88 Our findings provide strong
rationale for exploration of systemic metabolism as a th
89 These data provide a strong
rationale for further development of this approach, alon
90 ve or treatment-resistant NSCLC, providing a
rationale for further studies of avelumab in this diseas
91 traperitoneal seeding of EOC and provide the
rationale for future studies targeting Ncad in preclinic
92 life-threatening infections provides a clear
rationale for hematopoetic stem cell transplantation (HS
93 GR genomic binding and provide a biophysical
rationale for how promiscuous binding by GR allows funct
94 y homogeneous phenotype of LTBI, providing a
rationale for immunological risk stratification to impro
95 These results provide a
rationale for investigating the efficacy of combining se
96 Our findings provide a strong
rationale for investigation of the use of TKIs in combin
97 tive effects during inflammation; however, a
rationale for its apical expression has been lacking.
98 tagenic deaminase, human AID, and provides a
rationale for its regulation.
99 ng drives CRPC, and they offer a mechanistic
rationale for its therapeutic targeting in this disease.
100 These data provide the fundamental basis and
rationale for management of the axilla in clinical trial
101 increase tumour immunogenicity and provide a
rationale for new combination regimens comprising CDK4/6
102 g, we describe how we practice and provide a
rationale for our approach.
103 y of early HCV infection, and the scientific
rationale for PEP.
104 To determine TrkA expression in MCC as a
rationale for potential targeted therapy.
105 ls of decision making could provide a strong
rationale for precommitment strategies and that interdis
106 This study provides additional
rationale for scaling up violence prevention interventio
107 The report describes the consensus process,
rationale for selecting data elements to be reported, de
108 Finally, we provide a
rationale for stratification of human patients with lung
109 nic groups in Africa and Europe, providing a
rationale for such independent genomic datasets.
110 This review outlines the
rationale for surgical chromophore application, the weak
111 basis for the TNM staging system and is the
rationale for surgical resection of tumor-draining lymph
112 or influenza vaccine responses and provide a
rationale for targeted, ex vivo Ag-driven molecular prof
113 YC in malignant transformation and provide a
rationale for targeting EBV's roles in cell cycle modula
114 oxylmethylation on RAB GTPases and provide a
rationale for targeting ICMT in the treatment of metasta
115 These findings provide a
rationale for targeting MAOA and its associated molecule
116 Our results support the
rationale for targeting metabolism in sepsis with recomb
117 Our findings provide
rationale for targeting signaling via MET and CD44 durin
118 Our results support the
rationale for targeting synaptic and extrasynaptic GABAA
119 In addition, this report provides a
rationale for targeting the IL-23-TH17-pathway as a trea
120 ne responses in different cell types and the
rationale for targeting Tim-3 for effective cancer immun
121 ety profile, our results will provide with a
rationale for testing NSAIDs as potential chemoadjuvants
122 e a foundation for preclinical studies and a
rationale for testing whether NMDAR antagonists might be
123 Together the data provides a
rationale for the bi-partite nature of the ICP4 DNA reco
124 results establish a preclinical mechanistic
rationale for the clinical development of Axl inhibitors
125 results establish a preclinical mechanistic
rationale for the clinical development of AXL inhibitors
126 Overall, our findings provide a preclinical
rationale for the clinical development of MALT1 inhibito
127 Our findings provide a
rationale for the clinical evaluation of CFI-402257 in p
128 K4 as an oncogene in myeloma and provide the
rationale for the clinical evaluation of PAK4 modulator
129 These findings may support the
rationale for the clinical testing of peripherally restr
130 ation and inhibition, our study delivers the
rationale for the clinically observed phenomenon of resi
131 erent immune checkpoint modulators, form the
rationale for the design of immune checkpoint-based immu
132 ral ventromedial medulla provides additional
rationale for the development of CB2 receptor-selective
133 perties of proNGF and NGF and help provide a
rationale for the diverse biological effects of NGF and
134 These findings also serve to provide a
rationale for the evolution of the BCO-related outlier R
135 Our data provide a
rationale for the exploitation of immunotherapeutic appr
136 It provides a
rationale for the exploration of the CYGB pathway as a m
137 beta interaction results suggest a molecular
rationale for the higher AD prevalence among smokers, an
138 ng the nuclear export sequence), providing a
rationale for the increased cytoplasmic aggregation of R
139 al studies on SGLT2 inhibitors and provide a
rationale for the mode of action of these drugs.
140 Our data provide a mechanistic
rationale for the powerful ability of BAP1 to regulate g
141 which phages circumvent them, and provide a
rationale for the prevalence of pilus glycosylation in n
142 is, Leu, and Asp, respectively), providing a
rationale for the purine base specificity of S. venezuel
143 uring information transmission, suggesting a
rationale for the regulation of these information proces
144 ansporter NRAMP1 to the vacuole, providing a
rationale for the reversion of nramp3nramp4 phenotypes.
145 ism of AEP and DOT1L and suggest a molecular
rationale for the simultaneous inhibition of the MLL fus
146 ther, this structural information provides a
rationale for the stimulation of MalK ATPase activity by
147 ase revascularization exist, and much of the
rationale for the use of antiplatelet agents after endov
148 Specifically, we provide a molecular
rationale for the use of BET inhibitors to treat patient
149 ic BCR signaling, thus providing a molecular
rationale for the use of HSP90 inhibitors in the treatme
150 ur results offered a preclinical mechanistic
rationale for the use of PARP and ATR inhibitors to impr
151 ess, the efficacy of buparlisib supports the
rationale for the use of PI3K inhibitors plus endocrine
152 sual structure of these complexes provides a
rationale for their unexpected reactivity.
153 hat promotes OSC tumor growth, and provide a
rationale for therapeutic targeting of this pathway for
154 These data provide the
rationale for therapeutic use of avelumab in metastatic
155 n and to foster exercise tolerance provide a
rationale for therapeutic use of IL-37 in the treatment
156 Our finding provides a
rationale for therapeutically enhancing VISTA-mediated p
157 uitin ligase activity; however, a structural
rationale for these observations is not clear.
158 To provide a molecular
rationale for these observations, we study the Dbl-homol
159 The
rationale for this study was to evaluate the feasibility
160 In this paper, we review the
rationale for tOPV disposal and describe the global guid
161 Our data provide a
rationale for trials of host-directed therapies in TBDM,
162 Our data provide a structural
rationale for understanding the phenotypes of temperatur
163 Specifically, we discuss the
rationale for upcoming studies, and how novel therapies
164 IFNAR1 suppressed tumor growth providing the
rationale for upregulating IFNAR1 to improve anti-cancer
165 Information was sought on study design,
rationale for using deceased controls, application of th
166 injection, our findings provide a promising
rationale for validation of (18)F-DCFPyL in future prosp
167 interest in anti-TH2 biologics, we propose a
rationale for why they are particularly successful in co
168 RATIONALE:
Genetic polymorphisms in the asthma susceptib
169 RATIONALE:
High-flow nasal cannula (HFNC) improves the c
170 We summarize the
rationale historically used to support respiratory virus
171 RATIONALE:
How host genetic factors affect Mycobacterium
172 RATIONALE:
Human cardiac mesenchymal cells (CMSCs) are a
173 RATIONALE:
Human-induced pluripotent stem cell-derived c
174 RATIONALE:
Hypertension during pregnancy is a leading ca
175 RATIONALE:
Hypertrophic cardiomyopathy (HCM) is a protot
176 RATIONALE:
Idiopathic pulmonary fibrosis (IPF) involves
177 RATIONALE:
Idiopathic pulmonary fibrosis (IPF) is a chro
178 Familiarity with the
rationale,
implications, benefits, and limitations of ge
179 RATIONALE:
Improving the prospective identification of p
180 RATIONALE:
In patients with chronic heart failure, dayti
181 RATIONALE:
In the absence of a surgical lung biopsy, pat
182 RATIONALE:
In the endothelium, insulin stimulates endoth
183 RATIONALE:
In the original 1974 in vivo study of ventila
184 RATIONALE:
Increasing evidence indicates that alteration
185 RATIONALE:
Individuals with cystic fibrosis (CF) experie
186 RATIONALE:
Individuals with cystic fibrosis are at risk
187 RATIONALE:
Infants whose mothers smoked during pregnancy
188 RATIONALE:
Information from clinicians about the expecte
189 RATIONALE:
Intensive care unit (ICU)- and mechanical ven
190 Focused Update are highlighted, and a brief
rationale is provided.
191 The underlying
rationale is that negative emotions have been shown to b
192 RATIONALE:
Large-conductance calcium-activated potassium
193 RATIONALE:
Lipoprotein(a) [Lp(a)] is a low-density lipop
194 RATIONALE:
LKB1 (liver kinase B1) is a serine/threonine
195 RATIONALE:
Machine learning may be useful to characteriz
196 RATIONALE:
Maintaining optimal symptom control remains t
197 RATIONALE:
Maintenance of a surface immune barrier is im
198 RATIONALE:
Maternal depression and prenatal and early li
199 RATIONALE:
Matrix metalloproteinase-7 (MMP-7) has been i
200 RATIONALE:
Mechanisms contributing to chronic lung disea
201 RATIONALE:
Menopause is associated with changes in sex h
202 RATIONALE:
Mepolizumab, an IL-5-blocking antibody, reduc
203 RATIONALE:
Mesenchymal stromal cells (MSCs) are promisin
204 RATIONALE:
Myocardial delivery of human mesenchymal stem
205 RATIONALE:
Neurocognitive outcome after out-of-hospital
206 RATIONALE:
New therapies for refractory angina are neede
207 RATIONALE:
Nonclassical mouse monocyte (CX3CR1(high), Ly
208 RATIONALE:
Noninvasive ventilation (NIV) is increasingly
209 RATIONALE:
Notch signaling programs cardiac conduction d
210 RATIONALE:
Objective adherence to inhaled therapy by pat
211 RATIONALE:
Observational studies have found shorter leuk
212 tion through influencing DDR and support the
rationale of blocking TRIP12 to improve radiotherapy out
213 to understand the mechanisms underlying the
rationale of early cART onset.
214 lioma-promoting role of BCL6 and provide the
rationale of targeting BCL6 as a potential therapeutic a
215 s during tissue regeneration, and provides a
rationale of using appropriate stem cells for regenerati
216 The
rationale of using PHS donor designation that negatively
217 However, in this review, we outline the
rationale of why certain features of depression includin
218 RATIONALE:
Paracrine secretions seem to mediate therapeu
219 RATIONALE:
Patients with chronic obstructive pulmonary d
220 RATIONALE:
Pediatric pulmonary hypertension (PH) is a he
221 RATIONALE:
Phenotypic distinctions between severe asthma
222 RATIONALE:
Platelet hyperreactivity, which is common in
223 RATIONALE:
Post hoc analyses suggest that blood eosinoph
224 RATIONALE:
Postmitotic cells, such as cardiomyocytes, se
225 RATIONALE:
Pregnancy profoundly alters maternal physiolo
226 We herein report the
rationale,
preparation, biological evaluation, and mecha
227 RATIONALE:
Previous work indicates that ivacaftor improv
228 RATIONALE:
Prior sepsis studies evaluating antibiotic ti
229 RATIONALE:
Prognostication is important when counseling
230 RATIONALE:
Pulmonary arterial hypertension (PAH) is an o
231 RATIONALE:
Pulmonary nontuberculous mycobacterial diseas
232 RATIONALE:
Randomized data comparing triple therapy with
233 RATIONALE:
RBPs (RNA-binding proteins) have been describ
234 RATIONALE:
Recent advances have improved our ability to
235 RATIONALE:
Recombinant fragment of human surfactant prot
236 RATIONALE:
Reducing asthma exacerbation frequency is an
237 RATIONALE:
Respiratory-related hospitalizations of patie
238 RATIONALE:
Severe asthma (SA) is a heterogeneous disease
239 RATIONALE:
Severe, steroid-resistant asthma is the major
240 RATIONALE:
Sevoflurane improves gas exchange, and reduce
241 RATIONALE:
Single-center randomized controlled trials of
242 RATIONALE:
Smoking cessation counseling in conjunction w
243 RATIONALE:
Sputum neutrophil elastase and serum desmosin
244 RATIONALE:
Stratification of asthma at the molecular lev
245 RATIONALE:
Sympathetic nervous system control of inflamm
246 RATIONALE:
Temporal fluctuations have been demonstrated
247 There is a strong
rationale that the GOF activities, including alterations
248 RATIONALE:
The AMP-activated protein kinase (AMPK) is st
249 RATIONALE:
The austere setting of the intensive care uni
250 RATIONALE:
The burden of chronic obstructive pulmonary d
251 RATIONALE:
The Centers for Medicare and Medicaid Service
252 RATIONALE:
The development of a refractory period for Ca
253 RATIONALE:
The development of evidence-based treatment g
254 RATIONALE:
The findings of the NLST (National Lung Scree
255 RATIONALE:
The impact of cardioprotective strategies and
256 RATIONALE:
The Institute of Medicine (IOM) standards for
257 RATIONALE:
The interaction of circulating cells within t
258 RATIONALE:
The mechanistic foundation of vascular matura
259 RATIONALE:
The molecular mechanisms that regulate tuberc
260 RATIONALE:
The objective of this autopsy study was to de
261 RATIONALE:
The optimal nutritional strategy for critical
262 RATIONALE:
The pathogenesis of bicuspid aortic valve (BA
263 RATIONALE:
The prevalence of chronic obstructive pulmona
264 RATIONALE:
The prevalence of frailty (diminished physiol
265 RATIONALE:
The rate of decline of lung function is great
266 RATIONALE:
The relative actions and synergism between di
267 RATIONALE:
The Sepsis-3 Task Force updated the clinical
268 RATIONALE:
The sympathetic nervous system is a major med
269 RATIONALE:
The thoracic aortic wall can degenerate over
270 RATIONALE:
The TIME trial (Timing in Myocardial Infarcti
271 RATIONALE:
The transport of interstitial fluid and solut
272 RATIONALE:
Therapies that inhibit CETP (cholesteryl este
273 RATIONALE:
There are several methods to measure cardiomy
274 With this
rationale,
this study presents a validated lipidomics pl
275 RATIONALE:
Thymic stromal lymphopoietin (TSLP) is known
276 RATIONALE:
Thyroid hormones have been linked with variou
277 human liver cancer cells, providing a strong
rationale to elucidate the regulatory mechanisms for the
278 Overall, our results offer a mechanistic
rationale to employ PI3Kdelta inhibitors to selectively
279 Moreover, they provide a mechanistic
rationale to evaluate the combination of SHH and CXCR4 i
280 ll-mediated anti-tumor immune responses, and
rationale to explore the combination of immunotherapy an
281 east cancers, and they provide a mechanistic
rationale to explore the repurposing of drugs that targe
282 ificance: These findings offer a mechanistic
rationale to explore the repurposing of drugs that targe
283 , these results provide a strong mechanistic
rationale to investigate the therapeutic efficacy of tar
284 Our results provide a
rationale to pursue a means of increasing TGF-beta signa
285 In this review, we provide a
rationale to support continued investment in Cryptococcu
286 esident myeloid cells in GBM, establishing a
rationale to target infiltrating cells in this neoplasm.
287 ifically TPC, and they provide a therapeutic
rationale to target it in patients with glioblastoma.
288 s to immune escape in TNBC, and they offer a
rationale to target MUC1-C as a novel immunotherapeutic
289 ncer progression, establishing a preclinical
rationale to target this activation loop to further impr
290 ncer progression, establishing a preclinical
rationale to target this activation loop.
291 RATIONALE:
TRPM2 (transient receptor potential melastati
292 We have highlighted commonly cited
rationale used to support testing and the generally poor
293 RATIONALE:
Vascular endothelial growth factor (VEGF) is
294 RATIONALE:
Vascular endothelial mitochondrial dysfunctio
295 RATIONALE:
Ventilator-induced diaphragm dysfunction is a
296 RATIONALE:
Virtually all mesenchymal stem cell (MSC) stu
297 Based on such strong
rationale,
we encapsulated microRNA-34a in our well-esta
298 RATIONALE:
We previously derived and validated the Pedia
299 RATIONALE:
We previously identified two acute respirator
300 g the structural and dynamic investigations,
rationales were developed for the stabilizing effect at